Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.

Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R.

Prostate. 2002 Nov 1;53(3):211-7.

PMID:
12386921
2.

Prostate cancer prevention by silibinin.

Singh RP, Agarwal R.

Curr Cancer Drug Targets. 2004 Feb;4(1):1-11. Review.

PMID:
14965263
3.
4.

Prostate cancer chemoprevention by silibinin: bench to bedside.

Singh RP, Agarwal R.

Mol Carcinog. 2006 Jun;45(6):436-42. Review.

PMID:
16637061
5.

A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.

Singh RP, Agarwal R.

Mutat Res. 2004 Nov 2;555(1-2):21-32. Review.

PMID:
15476849
6.

Features of apoptotic cells measured by flow cytometry.

Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F.

Cytometry. 1992;13(8):795-808. Review.

7.

Chemopreventive efficacy of silymarin in skin and prostate cancer.

Deep G, Agarwal R.

Integr Cancer Ther. 2007 Jun;6(2):130-45. Review.

PMID:
17548792
8.

Mechanisms and preclinical efficacy of silibinin in preventing skin cancer.

Singh RP, Agarwal R.

Eur J Cancer. 2005 Sep;41(13):1969-79. Review.

PMID:
16084079
9.

Targeting silibinin in the antiproliferative pathway.

Li L, Zeng J, Gao Y, He D.

Expert Opin Investig Drugs. 2010 Feb;19(2):243-55. doi: 10.1517/13543780903533631. Review.

PMID:
20047507
10.

The use of silymarin in the treatment of liver diseases.

Saller R, Meier R, Brignoli R.

Drugs. 2001;61(14):2035-63. Review.

PMID:
11735632
11.

Silibinin--a promising new treatment for cancer.

Cheung CW, Gibbons N, Johnson DW, Nicol DL.

Anticancer Agents Med Chem. 2010 Mar;10(3):186-95. Review.

PMID:
20015009
12.

[An updated review at molecular pharmacological level for the mechanism of anti-tumor, antioxidant and immunoregulatory action of silibinin].

Wang HJ, Jiang YY, Lu P, Wang Q, Ikejima T.

Yao Xue Xue Bao. 2010 Apr;45(4):413-21. Review. Chinese.

PMID:
21355204
13.

Multitargeted therapy of cancer by silymarin.

Ramasamy K, Agarwal R.

Cancer Lett. 2008 Oct 8;269(2):352-62. doi: 10.1016/j.canlet.2008.03.053. Epub 2008 May 9. Review.

14.

New therapeutic potentials of milk thistle (Silybum marianum).

Milić N, Milosević N, Suvajdzić L, Zarkov M, Abenavoli L.

Nat Prod Commun. 2013 Dec;8(12):1801-10. Review.

PMID:
24555302
15.

Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Ting H, Deep G, Agarwal R.

AAPS J. 2013 Jul;15(3):707-16. doi: 10.1208/s12248-013-9486-2. Epub 2013 Apr 16. Review.

16.

An updated systematic review of the pharmacology of silymarin.

Saller R, Melzer J, Reichling J, Brignoli R, Meier R.

Forsch Komplementmed. 2007 Apr;14(2):70-80. Epub 2007 Apr 23. Review.

PMID:
17464157
17.

Advances in pharmacological studies of silymarin.

Rui YC.

Mem Inst Oswaldo Cruz. 1991;86 Suppl 2:79-85. Review.

18.

Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.

Bosch-Barrera J, Menendez JA.

Cancer Treat Rev. 2015 Jun;41(6):540-6. doi: 10.1016/j.ctrv.2015.04.008. Epub 2015 Apr 27. Review.

PMID:
25944486
19.

The role of flow cytometry in the study of cell growth in the rat anterior pituitary gland.

Toni R, Vitale M.

Eur J Histochem. 2000;44(4):315-24. Review.

PMID:
11214856
20.

Flavonoid antioxidant silymarin and skin cancer.

Singh RP, Agarwal R.

Antioxid Redox Signal. 2002 Aug;4(4):655-63. Review.

PMID:
12230878

Supplemental Content

Support Center